Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a randomized multicentre open label phase II study of Durvalumab following
Stereotactic Body Radiotherapy (SBRT) in patients with T1-2N0M0 NSCLC.
Patients will be randomized 1:1 to follow up or receiving Durvalumab every 4th week for 12
months